Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Ulta Beauty Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $54.69 (market cap $5.02B), while Ulta Beauty Inc trades at $604.65 (market cap $25.33B). The key difference: Ulta Beauty Inc is far larger — about 5× Travere Therapeutics Inc. Common Stock's market cap, and Ulta Beauty Inc is more actively traded (603,913 versus 2,060,842). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Ulta Beauty Inc for 92 Days on average.
| TVTX | ULTA | |
|---|---|---|
Market Cap | $5.02B | $25.33B |
Volume | 2,060,842 | 603,913 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $706.82 |
52-Week Low | $26.79 | $450.75 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $5.15B | $27.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
ULTA stock trades at $579.00, up 2.03% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 outlook, driven by e-commerce momentum. Valuation metrics show a P/E of 21.57 and robust profitability with a 46.12% ROE. The stock is near its R1 resistance at $574, with overall sentiment positive but noting margin pressures.
Outlook is positive with a consensus price target of $624.93, implying upside, but risks include flat traffic, promotional pressures, and margin compression. Long-term growth is supported by expansion into wellness and international markets, though near-term execution remains key.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
